Deep Sequencing Analysis of HBV Genotype Shift and Correlation with Antiviral Efficiency during Adefovir Dipivoxil Therapy

Yuwei Wang6,1*, Xuefeng Shan7,1*, Zhi Liang3*, Youlan Shan3, Wenxiang Huang4, Dazhi Zhang3, Aizhong Zen4, Xin Zhou3, Yao Zhao5, Xuyang Gong1, Ge Xu1, Xiuyu Zhang3, Juan Chen1*, Ailong Huang1*

1 Key Laboratory of Molecular Biology on Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, China, 2 School of Life Sciences, University of Science and Technology of China, Hefei, Anhui, China, 3 Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China, 4 Department of Infectious Diseases, the First Affiliated Hospital, Chongqing Medical University, Chongqing, China, 5 Pediatric Research Institute, Children's Hospital of Chongqing Medical University, Chongqing, China, 6 Department of Laboratory Medicine, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China, 7 Department of Pharmacy, the First Affiliated Hospital, Chongqing Medical University, Chongqing, China

☯ These authors contributed equally to this work.
* ahuang1964@163.com (ALH); yixin_xinyuan@163.com (JC)

Abstract

Background
Viral genotype shift in chronic hepatitis B (CHB) patients during antiviral therapy has been reported, but the underlying mechanism remains elusive.

Methods
38 CHB patients treated with ADV for one year were selected for studying genotype shift by both deep sequencing and Sanger sequencing method.

Results
Sanger sequencing method found that 7.9% patients showed mixed genotype before ADV therapy. In contrast, all 38 patients showed mixed genotype before ADV treatment by deep sequencing. 95.5% mixed genotype rate was also obtained from additional 200 treatment-naïve CHB patients. Of the 13 patients with genotype shift, the fraction of the minor genotype in 5 patients (38%) increased gradually during the course of ADV treatment. Furthermore, responses to ADV and HBeAg seroconversion were associated with the high rate of genotype shift, suggesting drug and immune pressure may be key factors to induce genotype shift. Interestingly, patients with genotype C had a significantly higher rate of genotype shift than genotype B. In genotype shift group, ADV treatment induced a marked enhancement of genotype B ratio accompanied by a reduction of genotype C ratio, suggesting genotype C may be more sensitive to ADV than genotype B. Moreover, patients with dominant
genotype C may have a better therapeutic effect. Finally, genotype shifts was correlated with clinical improvement in terms of ALT.

Conclusions
Our findings provided a rational explanation for genotype shift among ADV-treated CHB patients. The genotype and genotype shift might be associated with antiviral efficiency.

Introduction
The prevalence of chronic Hepatitis B virus (HBV) infection varies greatly in different parts of the world [1,2]. HBV has been classified into ten different genotypes (from A to J) based on the divergence of over 8% of the entire HBV genome sequence [3–5]. It has been reported that HBV genotype influences the outcome of HBV infection as well as the response to antiviral therapy [6–9].

HBV genotype shift has been reported previously in 18% to 32% of chronic hepatitis B (CHB) patients during antiviral therapy [10–15]. Recently, in a longitudinal study, Jardi et al observed a 53% genotype shift rate in Spanish patients under antiviral therapy using INNO-LiPA method [16]. Therefore, HBV genotype shift might be a common phenomenon in CHB patients during antiviral therapy. However, the underlying molecular mechanism of genotype shift still remains elusive.

So far, there are several possible explanations for HBV genotype shift in CHB patients undergoing antiviral therapy. Superinfection with another genotype during the treatment may result in genotype shift. Alternatively, the patient may initially carry a mixed infection with minor genotype undetectable by the current methods but the dominant genotype changes under the selection pressure from antiviral therapy. Although the last possibility of genotype shift has been widely proposed by many investigators, no solid supporting data are available experimentally [10–14]. This study aimed to investigate the mechanism of genotype shift in Chinese CHB patients and the influence of the HBV genotype on the disease course and treatment outcome, which was poorly documented.

Interestingly, the mixed infection rates of HBV genotypes vary significantly with different methods used. For example, in our previous study, we observed the rate of mixed genotype infection increased to 30% based on a more sensitive GQ-PCR method, while only 17% were detected with Sanger sequencing from the same sample pools [17]. However, with INNO-LiPA method, mixed infections rate reached 22% in 103 CHB patients [16]. With the development of the next generation sequencing technology, the rate of mixed infections of HBV among CHB patients might be higher than expected.

In this study, we demonstrate the successful application of deep sequencing technology to investigate the possible mechanism of genotype shift and its association with antiviral efficiency in CHB patients receiving antiviral therapy. We found high prevalence of mixed genotype infection before ADV treatment in CHB patients and the different sensitivity of distinct HBV genotypes to drug selection pressure might contribute to genotype shifts. Furthermore, we discovered that genotype C was more sensitive to ADV than genotype B and patients with dominant genotype C may have a better clinical improvement. Our data suggest that determination of genotype distributions of CHB patients using deep sequencing technology can be much accurate for diagnosis and monitoring during antiviral therapy and the different sensitivity of various genotypes to ADV therapy might provide a new strategy of antiviral therapy.
Methods

Patients and specimens

38 CHB patients treated with adefovir dipivoxil (ADV) for 48 weeks were selected based on the following criteria: HBV load greater than 1x10^5 copies/ml, ALT higher than 1.3 fold of the upper normal limit (UNL) and positive for HBeAg. Patients with liver cirrhosis, alcohol/drug abuse and HCV/HDV/HIV co-infection were excluded. Serum specimens were obtained from the 38 CHB patients who underwent ADV monotherapy from 2004 to 2005 in the First Affiliated Hospital of Chongqing Medical University. Written informed consent was obtained from all patients, and the study protocol was approved by the Ethical Committee of the Chongqing Medical University in accordance with the Declaration of Helsinki.

Establishment of genotyping analysis by deep-sequencing based on short sequence windows

The genotyping methodology was described detailedly in S1 Fig. Validation of genotyping analysis by deep-sequencing was described in S1 File and S2 Fig.

Direct and clonal sequencing for HBV genotype analysis

The method was detailed in S1 File.

Massively parallel deep sequencing for HBV genotyping

The method was described in detail in S1 File.

Statistical analysis

Statistical analysis was performed with ANOVA method to the obtained data and with Chi square test for comparisons between two groups. Results were considered statistically significant when $p<0.05$.

Results

Clinical laboratory data of the study population and genotype distribution according to direct sequencing method

Thirty-eight treatment-naïve patients with CHB were enrolled in the present study. All of the 32 male and 6 female patients were of hepatitis B e antigen (HBeAg) positive before ADV treatment with a median age of 30.3 (range: 19–52 years old). The clinical parameters of these HBV patients are summarized in Table A in S1 File. The genotype distribution was first determined by conventional direct sequencing method. Before ADV treatment, genotype B, genotype C and mixed B+C genotypes were detected in 25 (65.8%), 11 (28.9%) and 2 (5.3%) patients, respectively. After ADV treatment, genotype B, genotype C and mixed B+C genotypes were detected in 27 (71.1%), 4 (10.5%) and 7 (18.4%) patients, respectively. Genotype shifts were observed in 13 patients after ADV treatment (Table 1).

Genotype distribution according to clonal sequencing and deep sequencing methods

The genotype distribution and mixed infection rate were further determined by conventional cloning sequencing method. Before ADV treatment, genotype B was detected in 25 (65.8%), genotype C in 10 (26.3%) and mixed B+C genotypes in 3 patients (7.9%), respectively. The
Table 1. HBV genotype, ALT, HBeAg and HBV-DNA levels of 38 patients before and after ADV therapy.

| Case number | Genotype | ADV before | ADV after |
|-------------|----------|------------|-----------|
| 1           | B        | 184        | 185       |
|             | ALT      | 8.8        | 7.9       |
|             | HBeAg    | +          | +         |
| 2           | B        | 104        | 23        |
|             | ALT      | 7.6        | 5.5       |
|             | HBeAg    | +          | -         |
| 3           | B        | 94         | 17        |
|             | ALT      | 9.8        | 5.5       |
|             | HBeAg    | +          | -         |
| 4           | B        | 80         | 54        |
|             | ALT      | 9.9        | 7.8       |
|             | HBeAg    | +          | +         |
| 5           | C        | 157        | 35        |
|             | ALT      | 9.4        | 5.5       |
|             | HBeAg    | +          | -         |
| 6           | B        | 95         | 451       |
|             | ALT      | 10.4       | 8.3       |
|             | HBeAg    | +          | +         |
| 7           | B        | 235        | 16        |
|             | ALT      | 10.3       | 5.1       |
|             | HBeAg    | +          | -         |
| 8           | C        | 290        | 72        |
|             | ALT      | 8.6        | 5.7       |
|             | HBeAg    | +          | -         |
| 9           | C        | 203        | 35        |
|             | ALT      | 8.5        | 5.5       |
|             | HBeAg    | +          | +         |
| 10          | B        | 107        | 45        |
|             | ALT      | 8.9        | 6.3       |
|             | HBeAg    | +          | -         |
| 11          | C        | 260        | 47        |
|             | ALT      | 9.8        | 5.5       |
|             | HBeAg    | +          | -         |

(Continued)
| Case number | Genotype | ADV before | ADV after |
|------------|----------|------------|-----------|
| 12         | Genotype B | B          |           |
|            | ALT      | 611        | 86        |
|            | HBV-DNA  | 9          | 6.2       |
|            | HBeAg    | +          | +         |
| 13         | Genotype B | B          |           |
|            | ALT      | 87         | 103       |
|            | HBV-DNA  | 9.1        | 5.8       |
|            | HBeAg    | +          | -         |
| 14         | Genotype C | B/C        |           |
|            | ALT      | 300        | 31        |
|            | HBV-DNA  | 8.3        | 5.1       |
|            | HBeAg    | +          | +         |
| 15         | Genotype B | B          |           |
|            | ALT      | 136        | 71        |
|            | HBV-DNA  | 9.2        | 7.2       |
|            | HBeAg    | +          | +         |
| 16         | Genotype B | B/C        |           |
|            | ALT      | 351        | 42        |
|            | HBV-DNA  | 7.3        | 3         |
|            | HBeAg    | +          | -         |
| 17         | Genotype B | C          |           |
|            | ALT      | 151        | 26        |
|            | HBV-DNA  | 8.7        | 5.1       |
|            | HBeAg    | +          | -         |
| 18         | Genotype B | B/C        |           |
|            | ALT      | 161        | 18        |
|            | HBV-DNA  | 9.9        | 4.7       |
|            | HBeAg    | +          | +         |
| 19         | Genotype B/C | B          |           |
|            | ALT      | 50         | 29        |
|            | HBV-DNA  | 8.4        | 6.2       |
|            | HBeAg    | +          | -         |
| 20         | Genotype B | B          |           |
|            | ALT      | 193        | 31        |
|            | HBV-DNA  | 8.5        | 6         |
|            | HBeAg    | +          | -         |
| 21         | Genotype B/C | B          |           |
|            | ALT      | 235        | 18        |
|            | HBV-DNA  | 7.7        | 3.9       |
|            | HBeAg    | +          | -         |
| 22         | Genotype B | B          |           |
|            | ALT      | 59         | 19        |
|            | HBV-DNA  | 10.5       | 8.6       |
|            | HBeAg    | +          | +         |

(Continued)
| Case number | Genotype | ADV before | ADV after |
|-------------|----------|------------|-----------|
| 23          | Genotype B | B          | B         |
|             | ALT 130   | 120        |           |
|             | HBV-DNA 10.6 | 10.6       |           |
|             | HBeAg +    | +          |           |
| 24          | Genotype B | B          | B         |
|             | ALT 104   | 24         |           |
|             | HBV-DNA 10.7 | 8.2       |           |
|             | HBeAg +    | -          |           |
| 25          | Genotype B | B          | B         |
|             | ALT 63    | 68         |           |
|             | HBV-DNA 9.8 | 8.8       |           |
|             | HBeAg +    | +          |           |
| 26          | Genotype C | B/C        |           |
|             | ALT 73    | 24         |           |
|             | HBV-DNA 9.2 | 9.4       |           |
|             | HBeAg +    | +          |           |
| 27          | Genotype C | B          | B         |
|             | ALT 145   | 53         |           |
|             | HBV-DNA 9.7 | 8.2       |           |
|             | HBeAg +    | -          |           |
| 28          | Genotype C | C          | C         |
|             | ALT 282   | 58         |           |
|             | HBV-DNA 9.5 | 9.1       |           |
|             | HBeAg +    | -          |           |
| 29          | Genotype B | B          | B         |
|             | ALT 54    | 33         |           |
|             | HBV-DNA 9.3 | 8.1       |           |
|             | HBeAg +    | +          |           |
| 30          | Genotype B | B          | B         |
|             | ALT 252   | 242        |           |
|             | HBV-DNA 10.1 | 9.1      |           |
|             | HBeAg +    | +          |           |
| 31          | Genotype B | B          | B         |
|             | ALT 98    | 114        |           |
|             | HBV-DNA 10.6 | 10.1      |           |
|             | HBeAg +    | +          |           |
| 32          | Genotype B | B          | B         |
|             | ALT 45    | 49         |           |
|             | HBV-DNA 10.6 | 9.5      |           |
|             | HBeAg +    | +          |           |
| 33          | Genotype C | B/C        |           |
|             | ALT 62    | 67         |           |
|             | HBV-DNA 11 | 9.8        |           |
|             | HBeAg +    | +          |           |

(Continued)
minor genotype ratios in the 3 patients with mixed B+C genotypes were 6.5%, 9.5% and 27.8% (Fig 1A). After ADV treatment, genotype B was detected in 25 (65.8%), genotype C in 3 (7.9%) and mixed B+C genotypes in 10 patients (26.3%), respectively.

Deep sequencing (GS FLX platform) was also applied to investigate the genotype distributions of the 38 patients. In contrast to clonal sequencing result, mixed B+C genotypes were present in all the patients before ADV treatment. The detailed genotype distributions of the 13 patients with genotype shift are summarized in Fig 1B and Table 2. The minor genotype ratio in these patients ranged from 0.02% to 2.7% before ADV therapy. The genotype change of the 13 patients was further analyzed at several key time points including week 0, week 4, week 12 and week 48. As shown in Fig 1C, the fraction of the minor genotype in 5 patients (38%) with genotype shift increased gradually during the course of ADV treatment, in contrast to the slight alterations of minor genotype in 2 patient without genotype shift (Fig 1C). The fact indicates that the minor genotype becomes progressively dominant during ADV treatment, which may eventually lead to genotype shift. Therefore, the mechanism underlying genotype shift may be the change of different genotype ratios driven by certain pressures.

In view of the discrepancies observed, additional 200 CHB patients were analyzed with the deep sequencing method (Solexa platform). A high rate up to 95.5% of mixed HBV genotypes was observed by Solexa method (Fig 1D). Mixed B+C, A+B+C and B+C+D genotypes were observed in 187, 3 and 1 patients, respectively. These data further confirmed the prevalence of mixed genotype infections in patients before ADV treatment and may be prerequisite for genotype shift.

Table 1. (Continued)

| Case number | Genotype before | Genotype after |
|-------------|-----------------|----------------|
| 34          | Genotype C      | C              |
|             | ALT 74          | 29             |
|             | HBV-DNA 10.2    | 9              |
|             | HBeAg +         | -              |
| 35          | Genotype B      | B              |
|             | ALT 161         | 35             |
|             | HBV-DNA 10.8    | 9.7            |
|             | HBeAg +         | -              |
| 36          | Genotype B      | B              |
|             | ALT 72          | 46             |
|             | HBV-DNA 10.4    | 8.9            |
|             | HBeAg +         | +              |
| 37          | Genotype C      | B              |
|             | ALT 342         | 19             |
|             | HBV-DNA 10.2    | 9.5            |
|             | HBeAg +         | -              |
| 38          | Genotype B      | B              |
|             | ALT 50          | 38             |
|             | HBV-DNA 9.3     | 9.4            |
|             | HBeAg +         | -              |

Patients 3,7,13,16,17,19,20,24,37,38 with HBeAg seroclearance. Patients 2,8,11,21,27,28,34,35 with HBeAg seroconversion. ALT expressed as IU/L, HBVDNA expressed as log_{10} copies/mL.

doi:10.1371/journal.pone.0131337.t001
Genotype shifts correlated with selection pressure

To further investigate the underlying mechanism of genotype shift, association between genotype shift and selection pressure (including drug pressure and immune pressure) during antiviral therapy was analyzed. NAs inhibit HBV replication by targeting viral DNA polymerase, therefore, the change of HBV DNA load could reflect the response strength of HBV to drug selection pressure. Meanwhile, the change of serum HBeAg level or HBeAg seroconversion was used to indicate immune pressure strength of HBV as it functions to modulate immune response during chronic HBV infection. Based on serum HBV DNA level after ADV treatment, the 38 patients were classified into responder (HBV DNA load decreased by greater than $1 \times 10^2$ copies/ml) and non-responder groups (DNA load decreased by less than $1 \times 10^2$ copies/ml) (Fig 2A). The response to ADV induced by drug selection pressure was positively correlated with the rate of genotype shift, (Fig 2B). Furthermore, the rate of genotype shift was much higher in patients losing HBeAg during therapy (44%) relative to those remaining HBeAg-positive (25%) (Fig 2C). In contrast, absence of genotype shift was often observed in HBeAg-positive poor responder (data not shown). Collectively, these data support the
### Table 2. Genotypes distribution of the 13 patients with genotype shifts determined by clonal and deep sequencing.

| Patients | Clonal sequencing (clones) | Deep sequencing (reads) |
|----------|---------------------------|------------------------|
|          | Total (clones) B% (clones) C% (clones) | Total (reads) B% (reads) C% (reads) |
| 8 B      | 44 0 (0) 100 (44) | 532 1.88 (10) 98.12 (522) |
| A        | 36 91.7 (33) 8.3 (3) | 4240 92.02 (3902) 7.98 (338) |
| 9 B      | 31 0 (0) 100 (31) | 3802 1.03 (39) 98.97 (3763) |
| A        | 30 56.7 (17) 43.3 (13) | 4758 47.23 (2247) 52.77 (2511) |
| 11 B     | 32 0 (0) 100 (32) | 4107 0.02 (1) 99.98 (4106) |
| A        | 32 18.8 (6) 81.2 (26) | 3716 20.67 (768) 79.33 (2948) |
| 14 B     | 35 0 (0) 100 (35) | 1539 1.1 (17) 98.9 (1522) |
| A        | 30 26.7 (8) 73.3 (22) | 3041 27.39 (833) 72.61 (2208) |
| 16 B     | 32 100 (32) 0 (0) | 1795 98.22 (1763) 1.78 (32) |
| A        | 34 82.4 (28) 17.6 (6) | 3004 82.84 (2489) 17.16 (515) |
| 17 B     | 44 100 (44) 0 (0) | 1772 99.21 (1758) 0.79 (14) |
| A        | 30 13.3 (4) 86.7 (26) | 1259 3.14 (39) 96.86 (1220) |
| 18 B     | 35 100 (35) 0 (0) | 1383 99.78 (1380) 0.22 (3) |
| A        | 31 77.4 (24) 22.6 (7) | 3156 82.83 (2614) 17.17 (542) |
| 19 B     | 36 72.2 (26) 27.8 (10) | 1250 70.48 (881) 29.52 (369) |
| A        | 32 100 (32) 0 (0) | 5198 99.88 (5192) 0.12 (6) |
| 21 B     | 31 6.5 (2) 93.5 (29) | 2044 16.39 (335) 83.61 (1709) |
| A        | 31 100 (31) 0 (0) | 1839 97.72 (1797) 2.28 (42) |
| 26 B     | 34 0 (0) 100 (34) | 4545 0.88 (40) 99.12 (4505) |
| A        | 38 84.2 (32) 15.8 (6) | 3707 94.36 (3498) 5.64 (209) |
| 27 B     | 42 9.5 (4) 94.5 (38) | 4006 5.32 (213) 94.68 (3793) |
| A        | 35 100 (35) 0 (0) | 4216 97.3 (4102) 2.7 (114) |
| 33 B     | 33 0 (0) 100 (33) | 4724 0.19 (9) 99.81 (4715) |
| A        | 41 68.3 (8) 31.7 (13) | 5950 60.82 (3619) 39.18 (2331) |
| 37 B     | 32 0 (0) 100 (32) | 4205 0.14 (6) 99.86 (4199) |
| A        | 30 96.6 (29) 3.4 (1) | 3428 97.78 (3352) 2.22 (76) |

A refers to after treatment; B refers to before treatment.

doi:10.1371/journal.pone.0131337.t002

### Fig 2. Genotype shifts correlated with selection pressure.

A) 38 patients were classified into the responder (HBV DNA load decreased by greater than $1 \times 10^2$ copies/ml after ADV treatment) and non-responder groups (DNA load decreased by less than $1 \times 10^2$ copies/ml after ADV treatment). B) Genotype shift was observed in 41% (9/22) of the responders and 25% (4/16) of non-responders, respectively. C) The patients were divided into HBeAg-negative and HBeAg-positive group based on the level of HBeAg after drug treatment. Genotype shift was observed in 44% (8/18) of HBeAg-negative group and 25% (5/20) of HBeAg-positive group following the drug treatment.

doi:10.1371/journal.pone.0131337.g002
hypothesis that immune and drug pressure could induce genotype shift and different sensitivity of various genotypes to selection pressures may be the key factor contributing to genotype shift.

HBV genotype C was more sensitive to ADV than genotype B

Recently, HBV genotypes have been implicated in response to interferon therapy. Thus, we next determined the effects of HBV genotype on ADV response. According to the result of Sanger method, patients with genotype C showed higher rate of genotype shift than genotype B after ADV treatment. (B) The change of genotype B and C ratios in 38 patients before and after ADV treatment analyzed by deep sequencing method. \( \Delta \)Genotype B = Genotype B ratio after ADV treatment - Genotype B ratio before ADV treatment; \( \Delta \)Genotype C = Genotype C ratio after ADV treatment - Genotype C ratio before ADV treatment. (C) Genotype shift (GS) group showed increased ratio of genotype B accompanied by decreased ratio of genotype C after ADV treatment \( (p = 0.0175) \). (D) Group without genotype shift (NS) showed no significant difference of genotype B or C ratio after ADV treatment \( (p = 0.9381) \). (E) Comparison of change in ALT and the rate of HBeAg seroconversion after ADV therapy between patients with dominant genotype B and C. B, C, D and E, 38 patients were divided into genotype B group and genotype C group based on the genotype analyzed by deep sequencing method before ADV treatment.

doi:10.1371/journal.pone.0131337.g003

Fig 3. HBV genotype C was more sensitive to ADV than genotype B. (A) 38 patients were divided into genotype B group and genotype C group based on the genotype before ADV treatment analyzed by Sanger sequencing. Patients with genotype C showed higher rate of genotype shift than genotype B after ADV treatment. (B) The change of genotype B and C ratios in 38 patients before and after ADV treatment analyzed by deep sequencing method. \( \Delta \)Genotype B = Genotype B ratio after ADV treatment - Genotype B ratio before ADV treatment; \( \Delta \)Genotype C = Genotype C ratio after ADV treatment - Genotype C ratio before ADV treatment. (C) Genotype shift (GS) group showed increased ratio of genotype B accompanied by decreased ratio of genotype C after ADV treatment \( (p = 0.0175) \). (D) Group without genotype shift (NS) showed no significant difference of genotype B or C ratio after ADV treatment \( (p = 0.9381) \). (E) Comparison of change in ALT and the rate of HBeAg seroconversion after ADV therapy between patients with dominant genotype B and C. B, C, D and E, 38 patients were divided into genotype B group and genotype C group based on the genotype analyzed by deep sequencing method before ADV treatment.
shift group, ADV treatment induced a marked enhancement of genotype B ratio accompanied by a robust reduction of genotype C ratio (Fig 3C). However, the change of genotype B or C ratio before and after ADV therapy did not differ significantly in group without genotype shift (Fig 3D). On the other hand, the reduction of ALT and rate of HBeAg seroconversion after ADV therapy were more significant in patients with dominant genotype C before treatment compared with patients with dominant genotype B (Fig 3E), suggesting patients with dominant genotype C may have a better therapeutic effect. Collectively, these data revealed that HBV genotype C may be more sensitive to ADV than genotype B, and therefore is more prone to be associated with genotype shift during ADV therapy.

Correlations between genotype shift and clinical therapeutic parameters
Three clinical parameters, including ALT, HBV DNA load and HBeAg level were used to assess clinical therapeutic effect. After ADV treatment, patients with genotype shift showed a more significant reduction of ALT ($p = 0.0173$) compared with patients without genotype shift (Fig 4A). However, the rate of HBeAg seroconversion or seroclearance and change of HBV DNA load in patients with and without genotype shift did not differ significantly ($p > 0.05$) (Fig 4B and 4C). Together, these data suggested that genotype shift was correlated with clinical improvement in terms of ALT.

Discussion
In this study, a methodology based on deep sequencing technology was developed for the comprehensive and efficient genotype analysis of HBV from a large number of clinical samples. Our objective was to investigate the possible mechanism of HBV genotype shift in CHB patients under ADV therapy and its correlation with antiviral efficiency.

The reported genotype shift rates ranged from 18% to 32% depending on the source of clinical specimens and the methods used [10–15]. Recently, Jardi et al found that HBV genotype shifts were observed in 9 (53%) of 17 antiviral-treated patients from Spain using INNO-LiPA method and only 2 (22%) out of 9 patients of genotype shifts were mixed infection at baseline. Therefore, the hypothesis of mixed infection contributing to genotype shift could not be supported directly by Jardi’s findings due to small sample size and the low rate of mixed infection. In our study, both Sanger and deep sequencing methods were used for genotype analysis in 38 ADV-treated CHB patients from China. According to the Sanger method, 3 patients (7.9%) had mixed genotypes before treatment and 13 (34%) of 38 patients showed genotype shifts during treatment. However, all these 38 patients were shown to be of mixed infection with multiple genotypes by deep sequencing method. Furthermore, the high prevalence of mixed infection was further confirmed from another set of 200 CHB patients by deep sequencing. Our data revealed that deep sequencing-based genotyping methods are far more sensitive than conventional method previously used [18–21]. In addition, two different selected windows along the full HBV genome gave identical results of genotyping with respect to the same CHB patient, indicating that the obtained results from deep sequencing are reliable and comparable to the results derived from clonal sequencing. Therefore, we believe that the established deep sequencing methodology is a powerful tool for obtaining more profound insight into the study of genotype shifts and genotype-specific drug response during antiviral therapy.

Due to the high sensitivity of deep sequencing (with minor genotype detection limit of 0.02% in this study), the hidden minor genotypes in mixed infections could be detected before drug treatment. Based on the above analysis, it is reasonable to conclude that the detected genotype shift probably resulted from the initial existence of mixed genotypes. Since no single genotype conversion from B to C or from C to B was observed by deep sequencing in any of
our 38 study cases, meanwhile the divergence of ancestral HBV sequence into 8 genotypes is a long evolutionary process which can never be reproduced during a single patient’s lifespan, the mechanism of gene mutation might be excluded in this study. In a study from Germany involving 13 children suffering from chronic liver disease, HBV genotype conversion from types D to A was observed in 3 babies of 4 month old[11]. These findings suggested D/A genotype shift within such a short period could only be the result of initial mixed infections rather than gene mutation or superinfection. Furthermore, a dominant genotype change from C to B during the early antiviral therapy (day 22 post-treatment) also supported that genotype shift could only be caused by the initial mixed infections[14].

The genotype shifts associated with selection pressure during the treatment were also investigated. The results of both direct sequencing and clonal sequencing method revealed that rate
of mixed infection in 13 patients with genotype shift increased significantly after ADV therapy. Interestingly, enhancement of degree of mixed infection was also found after ADV treatment by deep sequencing GS FLX method in majority of 13 patients with genotype shifts. As control, 5 treatment-naive CHB patients with interval of more than one year showed no genotype shifts (data not shown). These data suggested that drug pressure may be an important factor to induce genotype shift. This hypothesis was further supported by the association analysis between genotype shift and selection pressure. The drug responders were found to have significantly higher rates of genotype shifts as compared to non-responders. Further comparisons between genotype shifts and the HBeAg seroclearance clearly demonstrated that the HBeAg seroclearance was also correlated with the high incidence of genotype shift. These results indicated that selection pressure (drug or immunologic) may be the external conditions inducing HBV genotype shift. Concordantly, Jardi et al also reported that genotype changes only occurred in CHB patients under antiviral therapy. Compared to the three years study by Jardi et al, our one year study appeared to have the lower rate of genotype shift (53% vs.34%). Among a group of 33 HIV/HHBV co-infected patients, 3–6 months of antiviral therapy also resulted in 18% of the HBV genotype shift[15]. It is likely that the incidence of genotype shift could be increased with the duration of NAs-related drug treatment, despite different patient sources in these studies. Since NAs is the current first-line antiviral therapy drug for CHB[22–24], genotype shift during treatment may become a common phenomenon with the widespread use of NAs.

Based on the literature, there are still no consensus regarding the correlations between genotypes and differential sensitivity of nucleotide analogues. Reports by Liu and Mirandola seemed to suggest the differential response of genotypes to different NAs[25,26]. Jardi results suggest that genotype A strains were likely present in an extremely low proportion in pre-treatment samples and were selected during therapy, possibly because of a lower sensitivity of HBV genotype A to nucleoside nucleotide/analogues. In contrast, Erhardt et al found that genotype A is more sensitive to interferon than genotype D in CHB patients[27]. In this study, we also observed the genotype change from C to B in the majority of 13 genotype shift patients (10/13). One possible explanation for the preferential switch from genotype C to genotype B (rather than from genotype B to genotype C) is that genotype C isolates have lower replication capacity than genotype B and are hence eliminated faster by nucleoside analogues. This idea is supported by an in vitro transfection study [28]. In contrast, 22 patients out of 25 patients without genotype shift were infected dominantly with the genotype B following one year ADV treatment. This observation suggests that genotype C may be more sensitive to ADV-treatment than genotype B. Furthermore, in genotype shift group, genotype B ratio increased significantly accompanied by a decrease of genotype C ratio after ADV therapy. Importantly, patients with dominant genotype C had more significant reduction of ALT and HBeAg after ADV treatment. Therefore, differential drug sensitivity may exist among different genotypes and may be the key factor in determining genotype shift observed in this study. Clinical efficacy of antiviral therapy may be associated with the genotype and genotype shift, both of which are influenced by the external drug selection pressure as exemplified above. Whether the preference in genotype shift is related to the genotype differential drug sensitivity or selection pressure during antiviral therapy remains to be investigated in the future.

In conclusion, we established a new deep sequencing strategy for HBV genotyping during antiviral therapy. For the first time, the rationale of HBV genotype shift has been adequately explained in this study. HBV genotype shifts are associated with the clinical improvement during the drug treatment and may become an important factor for consideration of future antiviral therapy.
Supporting Information

S1 Fig. The workflow of the short-window based HBV genotyping methodology.
(TIF)

S2 Fig. Establishment of short HBV DNA-based genotyping methodology using deep sequencing. (A) Expected average genotyping accuracy of different window lengths on the consensus HBV genome. The average accuracy of 0.95 or 0.99 could be achieved respectively, when a minimal window length of 75 bp or 200bp were used. (B) Expected genotyping accuracy of 100-bp long window starting from different positions. (C) Comparison of the observed genotype ratios (B & C) of 26 clinical specimens based on clonal sequencing and deep sequencing (GS FLX), respectively. The result indicated a high agreement of C.C. = 0.994 (Table C in S1 File). (D) Comparison of the observed genotype ratios (B & C) of 26 clinical specimens by deep sequencing with GS FLX and Solexa, respectively. The multiple correlation coefficient was C.C. = 0.998.
(TIFF)

S1 File. Materials and Methods.
(DOC)

Acknowledgments

We thank Dr. Gregory Lee (University of British Columbia, Vancouver) for manuscript preparation and comments. We also thank NoeGen Inc. (Gaithersburg, Maryland) for bioinformatics and statistical analysis.

Author Contributions

Conceived and designed the experiments: YWW XFS. Performed the experiments: YWW XFS. Analyzed the data: ZL ALH YWW XFS XZ. Contributed reagents/materials/analysis tools: YLS WXH DZZ AZZ. Wrote the paper: YZ XYG JC. Collected serum samples and patients’ data: YWW XFS GX XYZ.

References

1. Kurbanov F, Tanaka Y, Mizokami M. Geographical and genetic diversity of the human hepatitis B virus. Hepatol Res. 2010; 40:14–30. doi:10.1111/j.1872-034X.2009.00601.x PMID: 20156297

2. Cao GW. Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol. 2009; 15: 5761–5769. PMID: 19998495

3. Tran TT, Trinh TN, Abe K. New complex recombinant genotype of hepatitis B virus identified in Vietnam. J Virol. 2008; 82:5657–5663. doi:10.1128/JVI.02556-07 PMID: 18353958

4. Thuy PT, Aiestig E, Liem NT, Hannoun C, Lindh M. Genotype X/C recombinant (putative genotype I) of hepatitis B virus is rare in Hanoi, Vietnam-genotypes B4 and C1 predominate. J Med Virol. 2010; 82: 1327–1333. doi:10.1002/jmv.21775 PMID: 20572069

5. Tatematsu K, Tanaka Y, Kurbanov F, Sugauchi F, Mano S, Maeshiro T, et al. A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J Virol. 2009; 83: 10538–10547. doi:10.1128/JVI.00462-09 PMID:19640077

6. Kao JH, Chen DS. HBV genotypes and outcome of HBV infection. Hepatology.2005; 41:216. PMID: 15690486

7. Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: Recent advances. Journal of Gastroenterology and Hepatology. 2011; 26: 123–130. doi: 10.1111/j.1440-1746.2010.06541.x PMID: 21199523

8. Buster EH, Janssen HL. The importance of HBV genotype in HBeAg-positive chronic hepatitis B patients in whom sustained response is pursued. J Hepatol. 2011; 54:395–396. doi: 10.1016/j.jhep.2010.07.052 PMID: 21112108
9. Raimondi S, Maisonneuve P, Bruno S, Mondelli MU. Is response to antiviral treatment influenced by hepatitis B virus genotype? J Hepatol. 2010; 52:441–449 doi: 10.1016/j.jhep.2009.12.014 PMID: 20137824

10. Gerner PR, Friedt M, Oettinger R, Lausch E, Wirth S. The hepatitis B virus seroconversion to anti-HBe is frequently associated with HBV genotype changes and selection of preS2-defective particles in chronically infected children. Virology. 1998; 245:163–172. PMID: 9614877

11. Friedt M, Gerner P, Lausch E, Trubel H, Zabel B, Wirth S. Mutations in the basic core promoter and the precore region of hepatitis B virus and their selection in children with fulminant and chronic hepatitis B. Hepatology. 1999; 29:1252–1258. PMID: 10094972

12. Kato H, Orto E, Gish RG, Bzowej N, Newsom M, Sugauchi F, et al. Hepatitis B e Antigen in Sera From Individuals Infected With Hepatitis B Virus of Genotype G. Hepatology. 2002; 35:922–929. PMID: 11915040

13. Hannoun C, Krosgaard K, Horal P, Lindh M, Interpred trial group. Genotype Mixtures of Hepatitis B Virus in Patients Treated with Interferon. J Infect Dis. 2002; 186:752–759. PMID: 12198608

14. Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS. Evolution of Hepatitis B virus in an acute hepatitis B patient co-infected with genotypes B and C. J Gen Virol. 2006; 87:39–49. PMID: 16361416

15. Fallot G, Halgand B, Garnier E, Branger M, Gervais A, Roque-Afonso AM, et al. Recombination of hepatitis B virus DNA in patients with HIV. Gut. 2012; 61:1197e1208.15.

16. Jardi R, Rodriguez-Frias F, Schaper M, Giggi E, Tabernero D, Homs M, et al. Analysis of hepatitis B genotype changes in chronic hepatitis B infection: Influence of antiviral therapy. J Hepatol. 2008; 49:695–701. doi: 10.1016/j.jhep.2008.03.030 PMID: 18490074

17. Zhao Y, Zhang XY, Guo JJ, Zeng AZ, Hu JL, Huang WX, et al. Simultaneous Genotyping and Quantification of Hepatitis B Virus for Genotypes B and C by Real-Time PCR Assay. J Clin Microbiol. 2010; 48:3690–3697. doi: 10.1128/JCM.00741-10 PMID: 20720032

18. Law PT, Qin H, Ching AK, Lai KP, Co NN, He M, et al. Deep sequencing of small RNA transcriptome reveals novel non-coding RNAs in hepatocellular carcinoma. J Hepatol. 2013; 58:1165–1173. doi: 10.1016/j.jhep.2013.01.032 PMID: 23376363

19. Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, Thielen A, et al. Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. Clin Infect Dis. 2011; 53:732–742. doi: 10.1093/cid/cir493 PMID: 21890778

20. Ramirez C, Gregori J, Buti M, Tabernero D, Camós S, Casillas R, et al. A comparative study of ultra-deep pyrosequencing and cloning to quantitatively analyze the viral quasispecies using hepatitis B virus infection as a model. Antiviral Res. 2013; 98:273–283. doi: 10.1016/j.antiviral.2013.03.007 PMID: 23523552

21. Stoeck T, Behnke A, Christen R, Amaral-Zettle L, Rodriguez-Mora M, Chistoserdov A, et al. Massively parallel tag sequencing reveals the complexity of anaerobic marine protistan communities. BMC Biol. 2009; 7:72. doi: 10.1186/1741-7007-7-72 PMID: 19886985

22. Gordon SC, Krastev Z, Hortoban A, Petersen J, Sperl J, Dinh P, et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology. 2013; 58:505–513. doi: 10.1002/hep.26277 PMID: 23364953

23. Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, et al. Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients. J Hepatol. 2012; 57:508–514. doi: 10.1016/j.jhep.2012.04.037 PMID: 22659518

24. Dienstag JL. Benefits and Risks of Nucleoside Analog Therapy for Hepatitis B. Hepatology. 2009; 49: S112–S121. doi: S1016/j.jhep.2009.12.014 PMID: 19399795

25. Liu Y, Wang C, Zhong Y, Li X, Dai J, Ren X, et al. Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide-analogue-experienced Chinese patients with chronic HBV infection. J Viral Hepat. 2011; 18:e29–39. doi: 10.1111/j.1365-2893.2010.01360.x PMID: 21392168

26. Miranda S, Sebastiani G, Rossi C, Velo E, Erne EM, Varo A, et al. Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy. Antiviral Res. 2012; 96:422–429. doi: 10.1016/j.antiviral.2012.09.014 PMID: 23026293

27. Erhardt A, Blondin D, Hauck K, Sagir A, Kohnle T, Heintges T, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut. 2005; 54:1009–1013. PMID: 15951551

28. Qin Y, Tang X, Garcia T, Hussain M, Zhang J, Lok A, et al. Hepatitis B virus genotype C isolates with wild-type core promoter sequence replicate less efficiently than genotype B isolates but possess higher virion secretion capacity. J Virol. 2011; 85:10167–10177. doi: 10.1128/JVI.00819-11 PMID: 21775451